ReviewHealth science reports2026
Potential Effects of Aspirin on Transcription Factors Related to the Inflammation in Atherosclerosis: A Systematic Review.
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic Variants of BMI1 (rs1042059 and rs11591377) and Their Potential Role in Leukemia Susceptibility: A Narrative Review.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Atherosclerosis (AS), a major cause of cardiovascular mortality, involves chronic inflammation mediated by transcription factors such as NF-κB, PPARs, and AP-2α. Beyond its antiplatelet role, aspirin exerts anti-inflammatory effects that may influence these molecular pathways. This review systematically evaluates aspirin's modulatory effects on these transcription factors in AS. Methods: Relevant English-language studies (1980-2025) were retrieved from PubMed, ScienceDirect, and Google Scholar using keywords related to aspirin, atherosclerosis, and inflammation-related transcription factors. Results: Aspirin inhibits NF-κB activation, reduces proinflammatory cytokine production, and enhances PPAR and AP-2α signaling, contributing to anti-inflammatory and plaque-stabilizing effects. Clinical findings (e.g., ARRIVE, ASPREE) show variable cardiovascular outcomes, likely reflecting dose- and population-dependent responses. Conclusion: Aspirin modulates key inflammatory transcription factors in AS, offering potential benefits beyond platelet inhibition. Further studies should clarify AP-2α's mechanistic role and explore aspirin-based combination strategies tailored to patient-specific inflammatory profiles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.